In this EASL DeepDive held on 06 November 2024, Alice Turner, Pavel Strnad, and Nicola Brunetti discuss and explore the changing insights in the management of Alpha-1 Antitrypsin Deficiency.

Learning objectives:

1. Learn more about the role of heterozygosity of alpha-1 as a risk factor for chronic liver disease, especially in the context of other causes such as MASLD or alcohol
2. Get a better understanding of the extrahepatic manifestations and the need for a multi-disciplinary approach
3. Learn more about screening: who to screen and how
4. Discover the general unmet needs related to AAT, with an emphasis on awareness and timely diagnosis

This EASL DeepDive webinar is supported by Takeda Pharmaceuticals. Takeda Pharmaceuticals has had no input into the content of this EASL DeepDive.

Click here to see all EASL Video Podcasts on Apple Podcasts.